|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
2/28/2013 9:52:28 AM
CINCINNATI--(BUSINESS WIRE)--Camargo Pharmaceutical Services, the 505(b)(2) experts, is teaming with XenoTech, a leading contract research organization in the drug metabolism field, to present a webinar March 21 for drug developers who want to learn how to use the 505(b)(2) pathway to leverage preclinical studies to obtain regulatory approval faster and at a reduced cost. The webinar, “Utilizing the 505(b)(2) Pathway to Streamline and Accelerate a Drug Development Plan,” will explain how to identify potential candidates and the best process to obtain approval from the U.S. Food and Drug Administration. Andrea Hubbel, Camargo preclinical project manager, and Mark Horrigan, XenoTech senior mass spectrometry specialist and qualitative analytical chemistry group leader, will discuss how their team successfully developed an initial development plan using the 505(b)(2) program for a drug candidate designated for cardiovascular disease.
|
|
|
|
|
|
|
|
|
|
|